NCT02222155 - Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2015

Primary Completion Date

April 24, 2016

Study Completion Date

July 19, 2016

Conditions

ANCA-associated Vasculitis

Interventions

DRUG

CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids

DRUG

CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids

OTHER

Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids

Trial Locations (43)

Unknown

Huntsville

Phoenix

Tucson

Long Beach

Los Angeles

San Francisco

Aurora

Washington D.C.

Miami Springs

Tampa

Chicago

Kansas City

Lexington

Louisville

Shreveport

Charlestown

Duluth

Tupelo

St Louis

Reno

Lebanon

Albuquerque

Great Neck

Mineola

New York

Syracuse

Chapel Hill

New Bern

Columbus

Duncansville

Philadelphia

Providence

Charleston

Chattanooga

Amarillo

Austin

Houston

Salt Lake City

Seattle

Calgary

Toronto

Greenfield Park

Lévis